António Parada is a biologist, graduated at the University of Porto, Portugal. He joined Bial as a pre-clinical pharmacologist. In the same company, he was appointed to the team that managed the pre-clinical and clinical development of anti-parkinson and anti-convulsant (Zebinix) New Chemical Entities projects. After its MBA at the Portuguese Catholic University he setup and managed the technology transfer office at IBMC with licensing deals across Europe and USA. Parada was also the general manager of IBMC. He was vice-president of the European Association of technology transfer, responsible for setting up the first European Technology transfer training courses.
He founded the Biocodex group and left after six years with a turnover of 10 million euros. He was the Porto site manager of the “Centre of Excellence in phage display” of Ablynx. He was the manager of the Clinical Trial Unit of IPO Porto – cancer Hospital. He is a member of the Supervisory Board of EMBLEM. He is a board member at CDEMAC and the CEO of Fairjourney Biologics. He has 15 publications in peer reviewed journals on pharmacology and several others in botany, management, marketing and security.